Post-marketing clinical study of Topina tablets

Post-marketing clinical study of Topina tablets in patients with partial epilepsy (incremental dose comparative study)

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080220856

Enrollment

180

Registered

2009-09-09

Start date

2009-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Partial epilepsy

Interventions

investigational material(s) Generic name etc : Topina tablets (INN:topiramate) INN of investigational material : Therapeutic category code : 113 Antiepileptics Dosage and Administration for Investiga

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who continue the treatment of one or more antiepileptic drugs with same usage and dosage except Topina tablets Patients who experience one or more partial seizures in every four weeks regardless of the treatment of antiepileptic drugs except Topina tablets

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Efficacy	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026